News

The round was led by RiverVest Venture Partners, and included investments by New Enterprise Associates, BioMed Ventures and individual investors. Amplyx will use the funding to advance the

The open label trial is designed to evaluate the safety and efficacy of CMB305 in combination with atezolizumab versus atezolizumab alone in up to 80 patients with locally

RESTASIS is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca, a type of

This novel supplement can be added to an optimized serum free media for greater protein yield or used as a culture media in place of FBS or other

The company will interpret samples in rare disease and cancer as part of the project, which is being undertaken by Genomics England. The project intends to sequence 100,000

Thetanix is designed to treat paediatric Crohn’s disease (PCD), which is a chronic inflammatory bowel disease that causes inflammation, or swelling, across the lining of the digestive tract,

The Astellas dermatology portfolio consists of prescription and over-the-counter products, including Protopic, Locoid and Locobase, and Zineryt to treat eczema, acne and skin infections. The transaction, which is

NGP 555 is a first in class small molecule for the treatment and prevention of Alzheimer’s disease. NGP 555 is an amyloid modulator showing good brain penetration in

US-based Ocata develops and commercializes regenerative ophthalmology therapeutics. The company’s principal R&D and commercial efforts relate to its Regenerative Ophthalmology programs and involve development of therapies to treat